RecruitingPHASE1, PHASE2NCT05658640
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies
Studying Acute lymphoblastic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Princess Maxima Center for Pediatric Oncology
- Principal Investigator
- Paco Bautista, MD PhDPrincess Máxima Center
- Intervention
- Trametinib(drug)
- Enrollment
- 26 enrolled
- Eligibility
- 1-21 years · All sexes
- Timeline
- 2023 – 2029
Study locations (30)
- St. Anna Kinderspital, Vienna, Austria
- Universitair Ziekenhuis Gent, Ghent, Belgium
- Rigshospitalet Copenhagen, Copenhagen, Denmark
- Helsinki University Hospital, New Children's Hospital, Helsinki, Finland
- Hôpital des Enfants GH Pellegrin - CHU de Bordeaux, Bordeaux, France
- CHRU Lille - Hôpital Jeanne de Flandre, Lille, France
- Centre Léon Bérard, Lyon, France
- Hopital La Timone - Enfants, Marseille, France
- CHU Nantes Hôpital Mère-Enfant, Nantes, France
- Hôpital Robert Debré, Paris, France
- Universitätsklinikum Augsburg, Augsburg, Germany
- Charité Universitätsmedizin Berlin, Berlin, Germany
- Universitätsklinikum Essen, Essen, Germany
- Universitätsklinikum Frankfurt, Frankfurt, Germany
- Universitätsklinikum Münster, Münster, Germany
- +15 more locations on ClinicalTrials.gov
Collaborators
Innovative Therapies For Children with Cancer Consortium · IBFM · Fight Kids Cancer
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05658640 on ClinicalTrials.govOther trials for Acute lymphoblastic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05621291A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...National Cancer Institute (NCI)
- RECRUITINGPHASE2NCT07328503CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06738368Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic LeukemiaUniversity of Washington
- ENROLLING BY INVITATIONNCT07511959Autologous Exosomes From Platelet-rich Plasma as a Modern Tool of Regenerative DentistryWroclaw Medical University
- RECRUITINGNANCT07191119Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic LeukemiaSt. Jude Children's Research Hospital
- RECRUITINGPHASE2NCT07275762Y-4 to Treat the Postherpetic NeuralgiaNeurodawn Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07177183Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning FailureUniversity Hospital Ostrava
- ENROLLING BY INVITATIONNCT07515430The Association Between Gut Microbiome Composition Signature and Cancer-related Symptoms in Children With Acute Lymphoblastic LeukemiaSun Yat-sen University